Related Experiment Video
Updated: Aug 6, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
SHP-2 Expression Is a Positive Prognostic Biomarker in Non-Small-Cell Lung Carcinoma: Association with KRAS Mutation
Konstantinos Stamopoulos1, Georgios Pilichos2, Eleni Karatrasoglou3
1Second Department of Internal Medicine, General and Oncology Hospital of Kifissia "Agioi Anargyroi", Kifissia, 13561 Athens, Greece.
Summary
SHP-2 expression in lung cancer may predict immunotherapy response. This protein is linked to better outcomes, especially with KRAS mutations, suggesting it as a key biomarker for non-small cell lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Lung cancer remains a leading cause of cancer deaths globally.
- Immunotherapy has improved survival, but many patients do not respond adequately.
- Novel biomarkers and therapeutic targets are urgently needed for non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate the expression pattern of SHP-2 in NSCLC.
- To correlate SHP-2 expression with clinicopathological parameters and patient outcomes.
- To evaluate SHP-2 as a potential biomarker for immunotherapy response.
Main Methods:
- Immunohistochemistry was used to detect SHP-2 expression in 258 NSCLC cases.
- H-score was calculated to quantify SHP-2 expression levels.
- Statistical analyses correlated SHP-2 expression with survival and other clinical/molecular factors.
Main Results:
- SHP-2 expression was detected in 23.3% of NSCLC cases.
- SHP-2 expression positively correlated with smoking history, PD-L1 levels, and KRAS mutations.
- Positive SHP-2 expression was associated with improved clinical outcomes, particularly in patients receiving immunotherapy and those with KRAS mutations.
Conclusions:
- SHP-2 is a potential prognostic factor in NSCLC.
- SHP-2 may serve as a reliable biomarker for predicting response to immune checkpoint inhibitors.
- Combined SHP-2 expression and KRAS mutation status indicate prolonged survival.
